CD8A and neoplasm: Cross-presentation to CD8+ DCs leads to antigen presentation via MHCI complexes, resulting in the activation of CD8+ T cells which differentiate into cytotoxic T cells (CTLs) and enable a tumour antigen-specific immune response [21].